MX2022000504A - Polimorfos de (r)-n-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1 h-inden-1-il)-1-metil-1h-pirazol-4-carboxamida. - Google Patents

Polimorfos de (r)-n-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1 h-inden-1-il)-1-metil-1h-pirazol-4-carboxamida.

Info

Publication number
MX2022000504A
MX2022000504A MX2022000504A MX2022000504A MX2022000504A MX 2022000504 A MX2022000504 A MX 2022000504A MX 2022000504 A MX2022000504 A MX 2022000504A MX 2022000504 A MX2022000504 A MX 2022000504A MX 2022000504 A MX2022000504 A MX 2022000504A
Authority
MX
Mexico
Prior art keywords
inden
oxadiazol
polymorphs
carboxamide
pyrazole
Prior art date
Application number
MX2022000504A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Pfeiffer
Norma TOM
Denise Andersen
Qi Gao
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71995103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022000504(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MX2022000504A publication Critical patent/MX2022000504A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2022000504A 2019-07-17 2020-07-16 Polimorfos de (r)-n-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1 h-inden-1-il)-1-metil-1h-pirazol-4-carboxamida. MX2022000504A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875350P 2019-07-17 2019-07-17
PCT/US2020/042387 WO2021011807A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide

Publications (1)

Publication Number Publication Date
MX2022000504A true MX2022000504A (es) 2022-02-10

Family

ID=71995103

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000504A MX2022000504A (es) 2019-07-17 2020-07-16 Polimorfos de (r)-n-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1 h-inden-1-il)-1-metil-1h-pirazol-4-carboxamida.

Country Status (25)

Country Link
US (1) US20220315571A1 (https=)
EP (2) EP3999180B1 (https=)
JP (2) JP7624431B2 (https=)
KR (1) KR20220084008A (https=)
CN (3) CN114555590B (https=)
AU (1) AU2020313965A1 (https=)
BR (1) BR112022000494A2 (https=)
CA (1) CA3144975A1 (https=)
CL (1) CL2022000054A1 (https=)
DK (1) DK3999180T3 (https=)
ES (1) ES2980885T3 (https=)
FI (1) FI3999180T3 (https=)
HR (1) HRP20240713T1 (https=)
HU (1) HUE066891T2 (https=)
IL (1) IL289875A (https=)
LT (1) LT3999180T (https=)
MX (1) MX2022000504A (https=)
PH (1) PH12022550123A1 (https=)
PL (1) PL3999180T3 (https=)
PT (1) PT3999180T (https=)
RS (1) RS65611B1 (https=)
SI (1) SI3999180T1 (https=)
SM (1) SMT202400224T1 (https=)
TW (1) TWI865562B (https=)
WO (1) WO2021011807A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
PT4370116T (pt) 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
MX2024001294A (es) 2021-08-03 2024-02-13 Cytokinetics Inc Proceso para la preparacion de aficamten.
WO2024020468A1 (en) 2022-07-20 2024-01-25 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
EP4565230A1 (en) 2022-08-04 2025-06-11 Cytokinetics, Inc. Methods for treating obstructive hypertrophic cardiomyopathy
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
WO2024179422A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
US20250295639A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
MX2024001294A (es) * 2021-08-03 2024-02-13 Cytokinetics Inc Proceso para la preparacion de aficamten.

Also Published As

Publication number Publication date
CA3144975A1 (en) 2021-01-21
IL289875A (en) 2022-03-01
CN118908951A (zh) 2024-11-08
EP3999180B1 (en) 2024-05-08
PL3999180T3 (pl) 2024-09-23
NZ784930A (en) 2025-03-28
SMT202400224T1 (it) 2024-07-09
JP2022540668A (ja) 2022-09-16
DK3999180T3 (da) 2024-05-21
HRP20240713T1 (hr) 2024-09-13
JP2025061484A (ja) 2025-04-10
JP7624431B2 (ja) 2025-01-30
EP4487911A1 (en) 2025-01-08
ES2980885T3 (es) 2024-10-03
AU2020313965A1 (en) 2022-03-03
LT3999180T (lt) 2024-08-26
US20220315571A1 (en) 2022-10-06
WO2021011807A1 (en) 2021-01-21
SI3999180T1 (sl) 2024-07-31
RS65611B1 (sr) 2024-07-31
HUE066891T2 (hu) 2024-09-28
KR20220084008A (ko) 2022-06-21
FI3999180T3 (fi) 2024-06-18
TWI865562B (zh) 2024-12-11
CN114555590B (zh) 2024-09-10
CN114555590A (zh) 2022-05-27
CL2022000054A1 (es) 2022-10-07
TW202116763A (zh) 2021-05-01
PH12022550123A1 (en) 2022-12-19
EP3999180A1 (en) 2022-05-25
JP7755090B2 (ja) 2025-10-15
BR112022000494A2 (pt) 2022-03-03
PT3999180T (pt) 2024-06-25
CN119119018A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
CL2022000054A1 (es) Polimorfos de (r)-n-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-car- boxamida.
CL2022000089A1 (es) Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida.
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
EA202091506A1 (ru) Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
MX2022000708A (es) Formulaciones orales de inhibidores de sarcomeros cardiacos.
CO2018004124A2 (es) Compuestos heterocíclicos
CR20210247A (es) Nuevos compuestos heterocíclicos
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
BR112018001017A2 (pt) inibidores do receptor de fator-1 de estimulação de colônia (csf-1r)
EA201691302A1 (ru) Новые гетероциклические соединения
EA201992268A1 (ru) Новые пиридазиноновые гербициды
PH12019500664A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
UY38017A (es) Polimorfos de 4-[5-(3,5-dicloro-4-fluorofenil)-4,5-dihidro-5-(trifluorometil)-3-isoxazolil]-n-(2-etil-3-oxo-4-isoxazolidinil)-2-metilbenzamida
HUE062726T2 (hu) 1-(1,2-dimetilpropil)-N-etil-5-metil-N-piridazin-4-il-pirazol-4-karboxamid kristályos formái
BR112022003357A2 (pt) Compostos heterocíclicos
EA202191620A1 (ru) Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения
MX2020013518A (es) Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) del receptor de acido gamma-aminobutirico a alfa5 (gaba a alfa5).
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
AR091565A1 (es) N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de androgenos, su produccion y usos como productos medicinales
MX2021000068A (es) Formas y composiciones farmaceuticas de ivosidenib.
EP4288074A4 (en) Regulation of butvrophilin subfamily 3 member a1 (btn3a1, cd277)
MX386696B (es) Proceso para producir analogos de anillo de arilomicina
CO2021003295A2 (es) (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil)piperazin-1-carboxilato cristalino, composiciones y sus métodos de uso